<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="120855">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01698671</url>
  </required_header>
  <id_info>
    <org_study_id>MCV00010173</org_study_id>
    <nct_id>NCT01698671</nct_id>
  </id_info>
  <brief_title>InterGard Synergy Post-Marketing Surveillance Study</brief_title>
  <official_title>InterGard Synergy Post-Marketing Surveillance Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maquet Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maquet Cardiovascular</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the performance and safety of the InterGard Synergy
      vascular graft.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study of the device in patients with aneurysmal and occlusive disease of the abdominal aorta
      and peripheral arteries.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Graft Patency and Complications</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patency will be assessed by color-coded duplex ultrasound up to 6 months post implantation.
Complications including the occurrence of graft infections will be assessed up to post implantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mortality rate will be assessed up to 6 months post implantation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Aortic Aneurysm, Abdominal</condition>
  <condition>Occlusive Disease of Artery of Lower Extremity</condition>
  <arm_group>
    <arm_group_label>InterGard Synergy Vascular Graft</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>InterGard Synergy Vascular Graft</intervention_name>
    <arm_group_label>InterGard Synergy Vascular Graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients requiring an InterGard Synergy Vascular Graft

        Exclusion Criteria:

          -  Patients with contra-indications per InterGard Synergy Vascular Graft

          -  Patients with current graft infection

          -  Patients with a known allergy to collagen, triclosan or silver acetate

          -  Patients who require urgent or emergent surgery
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Max Zegelman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Krankenhaus Nordwest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Study Centers</name>
      <address>
        <city>Graz, Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Centers</name>
      <address>
        <city>Frankfurt, Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Centers</name>
      <address>
        <city>Heidelberg, Hamburg, Hanau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 24, 2013</lastchanged_date>
  <firstreceived_date>October 1, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
